Compare IDT & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IDT | MDXG |
|---|---|---|
| Founded | 1990 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | 1996 | N/A |
| Metric | IDT | MDXG |
|---|---|---|
| Price | $51.79 | $7.03 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $11.00 |
| AVG Volume (30 Days) | 248.4K | ★ 776.2K |
| Earning Date | 12-04-2025 | 10-29-2025 |
| Dividend Yield | ★ 0.47% | N/A |
| EPS Growth | ★ 10.35 | N/A |
| EPS | ★ 3.22 | 0.27 |
| Revenue | ★ $1,244,681,000.00 | $393,442,000.00 |
| Revenue This Year | $0.77 | $19.13 |
| Revenue Next Year | N/A | $2.11 |
| P/E Ratio | ★ $15.98 | $26.10 |
| Revenue Growth | 2.52 | ★ 14.77 |
| 52 Week Low | $44.77 | $5.79 |
| 52 Week High | $71.12 | $9.71 |
| Indicator | IDT | MDXG |
|---|---|---|
| Relative Strength Index (RSI) | 54.28 | 49.48 |
| Support Level | $50.60 | $6.62 |
| Resistance Level | $54.08 | $7.45 |
| Average True Range (ATR) | 2.08 | 0.26 |
| MACD | 0.27 | 0.02 |
| Stochastic Oscillator | 66.08 | 45.22 |
IDT Corp is a multinational holding company. It operates in the telecommunications and payment industries. It has four reportable business segments, Fintech, National Retail Solutions; net2phone and Traditional Communications, The Fintech segment is comprised of National Retail Solutions (NRS), an operator of a nationwide point of sale (POS) network providing payment processing, digital advertising, transaction data, and ancillary services, and BOSS Money, a provider of international money remittance and related value/payment transfer services. The net2phone segment provides unified cloud communications and telephony services to business customers.
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.